Aurobindo Pharma Limited FII & DII Activity

Today's Institutional Flow

FII cash inflow stands at ₹871.83 Cr while DII cash adds ₹643.35 Cr, indicating a combined net purchase of roughly ₹1,515 Cr in equities today, driven largely by renewed interest in large‑cap pharma stocks. Both foreign and domestic investors are net buyers, but the foreign side outpaces the domestic side by about ₹228 Cr, reflecting a modest reallocation from debt instruments to equity exposure. Overall participation reflects a broadly positive sentiment in the market, as investors appear to be positioning for an anticipated earnings‑season rally.

Trend vs 5-Day Average

The day's FII cash increase contrasts with a five‑day average outflow of ₹‑894.74 Cr, signalling a reversal in foreign buying pressure and suggesting that recent policy clarity may be encouraging earlier hesitation to re‑enter. Conversely, DII cash today remains well below its five‑day average of ₹2,592.03 Cr, suggesting domestic investors are still relatively restrained despite slightly improved risk appetite.

F&O Positioning Data

FII net exposure in futures and options rises to ₹643,395 Cr, showing a heavy tilt toward derivative positions as markets test price resilience ahead of upcoming regulatory announcements. The index futures long‑to‑short ratio of 1.2 indicates a modest net long bias among foreign traders, hinting at cautious optimism without overt speculation.

Healthcare Sector Flow

Recent weeks have seen the healthcare sector attract net FII purchases while DII activity hovers near neutral levels, underscoring a gradual shift toward defensive pharma holdings amid macro‑economic uncertainty.